- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05432479
Undersøgelse for at evaluere effektiviteten af et probiotikum til lindring af infantil koliksymptomer (PIXAR)
En randomiseret, dobbeltblindet, placebo-kontrolleret undersøgelse for at evaluere effektiviteten af et probiotikum til lindring af infantile koliksymptomer
This study evaluates the efficacy of single strain probiotic administered in a form of a sachet in the treatment of infant colic in infants 3-12 weeks old.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Atlantia Food Clinical Trials
-
-
-
-
Maharashtra
-
Pune, Maharashtra, Indien, Pune 411 041
- Pulse Multispeciality Hospital,
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Gestational age of minimum 37 weeks.
- Birthweight of minimum 2500 g (5.5 lb.).
- Age of greater than 3 weeks and less than 12 weeks at enrolment.
- Confirmed Infantile colic defined as: parental report of crying and/or fussing ≥3 hours/day for ≥3 days/week, confirmed prior to enrolment with an infant behaviour diary recording >3 hours of crying in a 24-hour period (eDiary App completed daily during run-in period & for duration of study).
- Participant Informed Consent form signed by parent or legal guardian.
- Infant is considered healthy following physical exam.
- Parents/Caregivers are willing to comply with the trial procedures, and the mother of the infant can attend all three trial visits
Exclusion Criteria:
- Use of antibiotics by the infant within 2-weeks prior to the screening visit or during the run-in period of the trial.
- Use of probiotic supplements from child's birth to enrolment (this includes infant formulas containing probiotics).
- Need for hospitalization (defined as readmission to a hospital ward after initial discharge following delivery).
- Congenital disorders that, in the opinion of the investigator, would impact the gastrointestinal tract.
- Failure to thrive.
- Known lactose or gluten intolerance.
- Known allergy to cow's milk proteins, fish, or any of the substances of the trial product or placebo.
- Known other causes for abdominal pain (e.g., pyloric stenosis).
- Participation in any other interventional clinical study.
- Immuno-compromised participant or participant with other severe chronic disorder.
- Use of probiotic supplements by breastfeeding mother from child's birth to enrolment.
- Use of antibiotics by breastfeeding mother within 2-weeks prior to the screening visit or during the run-in period of the trial.
- Any Participant/Parent/Caregiver who is an employee of the investigational site or an Atlantia Clinical Trials employee or their close family member or a member of their household.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Active
Arm receiving investigation product (probiotic) |
Single strain probiotic in a form of a sachets with a daily dose of 1.0E+9 Colony Forming Unit (CFU) per day for 4 weeks |
|
Placebo komparator: Placebo
Arm receiving placebo |
Placebo |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in cry and fuss time
Tidsramme: Day 0, Day 28
|
eDiary parent reported cry and fuss time |
Day 0, Day 28
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in cry and fuss time
Tidsramme: Day 0, Day 7
|
eDiary parent reported cry and fuss time |
Day 0, Day 7
|
|
Resolution of colic symptoms
Tidsramme: Day 0, Day 28
|
Reduction of cry and fuss time (parent reported) greater than 90% comparing to baseline |
Day 0, Day 28
|
|
Change in cry and fuss time bouts
Tidsramme: Day 0, Day 7, Day 28
|
eDiary parent reported cry and fuss bouts |
Day 0, Day 7, Day 28
|
|
Change in sleeping time
Tidsramme: Day 0, Day 7, Day 28
|
eDiary parent reported sleep time |
Day 0, Day 7, Day 28
|
|
Change in the use of rescue medications
Tidsramme: Day 0, Day 28
|
Change in the proportion of participants needing to use rescue medications between the study arms |
Day 0, Day 28
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in maternal quality of life and mental health
Tidsramme: Day 0, Day 28
|
Change in maternal QoL using WHO QOL/BREF (improvement marked by increase in the total score) |
Day 0, Day 28
|
|
Change in maternal quality of life and mental health
Tidsramme: Day 0, Day 28
|
Change in maternal QoL using MAPP/QoL (improvement marked by increase in the total score) |
Day 0, Day 28
|
|
Resolution of colic symptoms
Tidsramme: Day 0, Day 28
|
Reduction of cry and fuss time (parent reported) greater than 50% comparing to baseline |
Day 0, Day 28
|
|
Change in the use of rescue medication drops
Tidsramme: Day 0, Day 7, Day 28
|
Change in the number of rescue medication drops used between the study arms |
Day 0, Day 7, Day 28
|
|
Change in duration of daily crying and fussing episodes
Tidsramme: Day 0, Day 7, Day 28
|
Change in mean duration per crying and fussing episode per day |
Day 0, Day 7, Day 28
|
|
Changes in gut microbiome composition
Tidsramme: Day 0, Day 28
|
Changes in microbiome composition as measured by changes in alpha and beta diversity of the gut microbiome throughout the study as compared to placebo and baseline |
Day 0, Day 28
|
|
Change in fecal calprotectin concentration
Tidsramme: Day 0, Day 28
|
Changes in fecal calprotectin concentration throughout the study as compared to placebo and baseline |
Day 0, Day 28
|
|
Adverse Events (AEs)
Tidsramme: From enrolment to Day 35
|
Reports of Adverse Events (AEs) and Serious Adverse Events (SAEs) |
From enrolment to Day 35
|
|
Change in vital signs
Tidsramme: Day 0, Day 28
|
Changes in vital sign measurements (heart rate [bpm] and body temperature [°F]) collected during the study will be summarised by treatment group |
Day 0, Day 28
|
Samarbejdspartnere og efterforskere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- PCTB202010
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .